|
WO2021055742A1
|
|
Soluble mediators for predicting systemic lupus erythematosus activity events
|
|
WO2020243228A1
|
|
Antibodies to polyphosphate decrease fibrosis
|
|
WO2020092969A1
|
|
Monoclonal antibodies to eltd1 and uses thereof
|
|
WO2020101880A1
|
|
Compositions and methods of treating systemic lupus erythematosus
|
|
WO2020081204A1
|
|
Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity
|
|
US2021093599A1
|
|
N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated tgf-beta activation and signaling
|
|
EP3755434A1
|
|
Treatment for age- and oxidative stress-associated muscle atrophy and weakness
|
|
WO2019112996A1
|
|
Method and compositions for treating obesity and insulin resistance
|
|
CN111770762A
|
|
Treatment of bone diseases caused by defects in intracellular protein trafficking
|
|
AU2018335160A1
|
|
Treatment of drug resistant gliomas
|
|
US2018364229A1
|
|
Biomarkers for Assessing Risk of Transitioning to Systemic Lupus Erythematosus Classification and Disease Pathogenesis
|
|
WO2018222741A1
|
|
Bispecific antibodies for the treatment of streptococcus pneumonia
|
|
CN110462062A
|
|
Systemic loupus erythematosus Disease Activity, intensity and the biomarker of acute attack
|
|
US2017220678A1
|
|
Automated scientific error checking
|
|
EP3383308A1
|
|
Geared orthodontic buccal tube
|
|
WO2017070547A1
|
|
Antibodies to tripartite motif containing protein 38 (trim38) and severity of disease in sjogren's syndrome
|
|
WO2017053838A1
|
|
Biomarkers for assessing subjects with multiple sclerosis
|
|
EP3340972A1
|
|
Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
|
|
WO2016205027A1
|
|
Ubiquitin interacting motif peptides as therapeutics
|
|
AU2016203760A1
|
|
Monoclonal antibodies against activated and unactivated protein c
|
